Stefan Arver joins the Board of Karessa Pharma

Stefan Arver, a prominent fellow, chief physician and section manager at the Karolinska University Hospital, has been appointed a new member of Karessa's Board of Directors. His recruitment further strengthens the company's expertise in the field of male sexual health.

"With Stefan Arver we are gaining world-leading expertise in the field of male sexual health. He will be extremely important for Karessa's continued development of the next generation of pharmaceutical products treating erectile dysfunction," says Torbjörn Kemper, CEO of Karessa.  

Stefan Arver has been involved in the development of andrology in Sweden, the branch of medicine that deals specifically with men. As a research group leader, including at the Karolinska Institute, he has participated in the development and evaluation of treatment methods for sexual dysfunction/erectile problems, and has been responsible for some 20 studies since the beginning of the 1990s. For a long time, Arver has worked actively to spread knowledge about male illnesses and the need for medical treatment. He has achieved this through lectures, TV and radio programmes, newspaper articles and as the author of scientific articles and several Swedish and international books.  

"I am greatly looking forward to providing Karessa with additional medical expertise and knowledge, particularly when it comes to the development work and the studies that are necessary to create the next generation of medicinal products to treat erectile dysfunction. With my knowledge and experience, I hope to be able to add a patient's perspective and to contribute towards direct patient-oriented product development," says Stefan Arver. 

40 per cent of all men affected
Almost half of all men above the age of 40 suffer from some degree of erectile dysfunction, i.e. the inability to achieve and maintain an erection that is sufficient to enable sexual activity. Karessa aims to develop the next generation of pharmaceutical products treating erectile dysfunction, offering a faster and more reliable effect than the drugs that currently dominate the market.

Karessa's solution comprises a unique concept, combining the company's patented drug delivery platform with clinically tested and proven substances (e.g. Sildenafil and Tadalafil). This combination is creating major patient benefits in the form of fast and reliable effects. The actual platform comprises a film resembling a postage stamp. This is applied to the oral mucosa, whereupon the active substances are delivered directly into the bloodstream. This facilitates a rapid uptake and a shorter time until the drug takes effect – and a reduced need for planning. Furthermore, the uptake is also not affected by the simultaneous consumption of food and drink. 

"A pharmaceutical product with a fast, direct and reliable effect; a pharmaceutical product that does not require any extended preparations or planning is something that many men want. Karessa's concept and technology are providing the potential to satisfy the desire for rapid onset," says Stefan Arver.

 Listing on Nasdaq Stockholm First North on 10 February 2015
The listing of Karessa on Nasdaq Stockholm First North is a natural step in the work aimed at establishing Karessa as a world-leading company on the growing market for pharmaceutical products treating erectile dysfunction. The problem is widespread, the market is enormous and Karessa's ambition is to contribute with a better solution than those currently available. The first day of trading is 10 February 2015.

On Karessa's new website you will find a film showing an interview with Stefan Arver.

For further information, please contact:
Torbjörn Kemper
CEO
+46 (0)8-768 22 33
torbjorn.kemper@karessa.se

About Karessa Pharma AB
Karessa Pharma AB is developing and commercialising the next generation of pharmaceutical products to treat erectile dysfunction. Karessa's concept is based on a patented drug delivery film, which is combined with clinically tested and proven active substances. This combination results in a pharmaceutical product that delivers both a direct and reliable effect.  www.karessa.se

Tags: